BioSpace News Archive

Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019 Positive Cash Flow for the Quarter Conference Call Today at 8:30am Eastern Time

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.575 per share payable on July 31, 2020 to shareholders of record at the close of business on June 30, 2020, representing an increase of approximately 11% versus the prior year and unchanged from the previous quarter.

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22 patients in

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams , who served as Chairman of the Board of Directors since

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), wh

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to participate in two upcoming investor conferences.

Merged Companies to Operate as Synergistic Divisions. New Corporate Identity Focuses on Optimizing Bioavailability, Absorption, Quality and Performance of Human, Animal and Agricultural Products. [05-May-2020] SOUTH EASTON, Mass. , May 5, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of bro

Saama Technologies, Inc., the #1 AI clinical analytics platform company, and iNDX.Ai, a leading Multi-omics Data Analytics and translational research platform company, announced the launch of the new COVID-19 Command Center.

A new fund raising round for Defymed, to allow the entry into clinical phase of its ExOlin® device

Sharps Compliance Corp. announced that David P. Tusa, Chief Executive Officer has been invited to participate in Oppenheimer’s 5th Annual Emerging Growth Conference, which will take place virtually on Tuesday, May 12, 2020.